Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: The importance of lipophilicity for binding and metabolism

Drug Metabolism and Drug Interactions

Volumn 21, Issue 3-4, 2006, Pages 213-231

  Lewis, David F V ^a   Lake, Brian G ^a,b   Ito, Yuko ^c   Anzenbacher, Pavel ^d  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

^c KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CYP2B subfamily; Cytochromes P450; Drug metabolism; QSARs

Indexed keywords

ALKOXYRESORUFIN DERIVATIVE; BARBITURIC ACID DERIVATIVE; CYTOCHROME P450 2B; CYTOCHROME P450 2B6; DIMETHYLANILINE MONOOXYGENASE; HALOGENOALKANE; HYDROCARBON; PRIMARY ALIPATHIC AMINE; TOLUENE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CORRELATION ANALYSIS; DRUG BINDING; DRUG METABOLISM; ENZYME SUBSTRATE; EQUILIBRIUM CONSTANT; LIPOPHILICITY; LOGLINEAR MODEL; MAMMAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

EID: 33745654574     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2006.21.3-4.213     Document Type: Article

References (33)

1. Lewis DFV. Guide to Cytochromes P450 Structure and Function. London: Taylor & Francis, 2001.
2. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2002; 58: 737-747.
3. Guengerich FP. Cytochrome P450. In: Ioannides C, ed. Enzyme Systems that Metabolize Drugs and Other Xenobiotics. New York: Wiley, 2002; 33-65.
4. rd Ed. New York: Plenum Kluwer, 2005.
5. Lewis DFV. Cytochromes P450: Structure, Function and Mechanism. London: Taylor & Francis, 1996.
6. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
7. Ioannides C, ed. Cytochromes P450: Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996.
8. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.
9. Nims RW, Lubet RA. The CYP2B subfamily. Ioannides C, ed. Cytochromes P450: Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996, 135-160.
10. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347: 321-337.
11. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 1999; 31: 719-754.
12. Al-Gailany KAS, Houston JB, Bridges JW. The role of substrate lipophilicity in determining type 1 microsomal P450 binding characteristics. Biochem Pharmacol 1978; 27: 783-788.
13. Lewis DFV, Dickins M. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev 2003; 35: 1-18.
14. Lewis DFV. Quantitative structure-activity relationships (QSARs) within human cytochromes P450 substrates of the CYP2 family. Toxicol in Vitro 2004; 18: 89-97.
15. Lewis DFV, Lake BG. Molecular modelling of human CYP2B isoforms and their interaction with substrates, inhibitors and redox components. Xenobiotica 1997; 27: 443-487.
16. Lewis DFV, Eddershaw PJ, Dickins M, Taribt MH, Goldfarb PS. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem-Biol Interact 1998; 115: 175-199.
17. Lewis DFV, Lake BG, Dickins M, Eddershaw PJ, Tabit MH, Goldfarb PS. Molecular modelling of the phenobarbital-inducible P450 isoforms: CYP2B1, CYP2B4 and CYP2B6 by homology with the substrate-bound CYP102 crystal strucutre, and evaluation of CYP2B substrate binding affinity. Xenobiotica 1999; 29: 361-393.
18. Lewis DFV, Dickins M, Goldfarb PS. Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions. Drug Metab Drug Interact 2003; 19: 115-135.
19. Burke MD, Mayer RT. Differential effects of phenobarbitone and 3-methyl-cholanthrene induction in the hepatic microsomal metabolism and cytochrome P40 binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem-Biol Interact 1983; 45: 243-258.
20. Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9Å resolution. J Biol Chem 2004; 279: 27294-27301.
21. Lewis DFV, Lake BG, Dickins M. Quantitative structure-activity relationships within a homogous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modelling studies on key members of the resorufin series with CYP2C5-dervied models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4. Xenobiotica 2004; 34: 501-513.
22. Lewis DFV. COMPACT and the importance of frontier orbitals in toxicity medicated by the cytochrome P450 mono-oxygenase system. Toxicol Model 1995; 1: 85-97.
23. Lewis DFV. Frontier orbitals in chemical and biological activity: quantitative relationships and mechanistic implications. Drug Metab Rev 1999; 31: 755-816.
24. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 2000; 60: 293-306.
25. Lewis DFV, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discovery Today 2004; 9: 530-537.
26. Sipal Z, Anzenbacher P, Putz Z, Chlumsky J, Krivanova O. Interaction of cytochrome P450 with hydrocarbons. Acta Biol Med Germanica 1979; 38: 483-494.
27. Lewis DFV. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology 2003; 11: 43-73.
28. Lewis DFV, Ioannides C, Parke DV. A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P450 (CYP2B4) and also their hydroxylation rates. Biochem Pharmacol 1995; 50: 619-695.
29. S values of some homologous series of barbiturates and the relationship with the lipophilicity and metabolic clearance. Biochem Pharmacol 1977; 26: 2117-2120.
30. MacDonald TL, Gutheim WG, Martin RB, Guengerich FP. Oxidation of substituted N,N-demethylanilines by cytochrome P450: estimation of the effective oxidation-reduction potential of cytochrome P450. Biochemistry 1989; 28: 2071-2077.
31. Jefcoate GR, Gaylor JL, Calabrese RL. Ligand interactions with cytochrome P450. 1. Binding of primary amines. Biochemistry 1969; 8: 3455-3463.
32. White RE, McCarthy M. Active site mechanics of liver microsomal cytochrome P450. Arch Biochem Biophys 1986; 246: 19-32
33. Eldirdiri N. Uptake and metabolic effects of some inhaled halogeno-alkanes. Ph.D. Thesis, University of Surrey, Guildford, Surrey, UK, 1992.